Navigation Links
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia

- Study Will Assess Drug's Benefit, Alone and With Lipitor(R), in Overweight or Obese Patients with High Cholesterol and Triglycerides -

HAYWARD, Calif., Sept. 25 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug's effect on dyslipidemia, insulin-resistance and obesity.

Preclinical and clinical testing of MBX-8025 indicates that the drug has the potential to improve a number of lipid parameters that are abnormal in different types of dyslipidemia, including high LDL (or "bad") cholesterol, high Apo B-100 (the atherogenic lipoprotein), low HDL (or "good") cholesterol and high triglycerides (fats). In addition, MBX-8025 has been shown to exhibit positive effects on insulin sensitization and body weight. The randomized, double-blind Phase 2 trial will assess the potential of the drug alone and in combination with Lipitor(R) (atorvastatin).

"Although high LDL levels are widely treated as a risk factor for heart disease, many patients are unable to reach increasingly low LDL targets on a statin alone. Additionally, existing drugs do a poor job of targeting the entire range of different lipid disorders that contribute to cardiac risk. We believe this trial will provide us crucial evidence in assessing the ability of MBX-8025 to lower Apo B-100, LDL and triglyceride levels, as well as raise HDL levels, improve insulin sensitivity and reduce body weight," said David B. Karpf, M.D., the chief medical officer of Metabolex. "In addition, we are testing the drug in conjunction with Lipitor, the best-selling lipid-lowering drug in the world, to determine whether combination therapy with a statin will be well tolerated and lead to even better results."

The study will enroll 180 overweight or obese non-diabetic patients and assess two different doses of MBX-8025, given over an 8-week treatment period, both alone and in combination with Lipitor(R). The primary endpoint is the reduction in Apo B-100 compared with placebo. Secondary endpoints include measurements of the effect of treatment on LDL, HDL, triglycerides and body weight and composition. Metabolic parameters, including glucose and insulin levels, will also be assessed.

MBX-8025 regulates fatty acid degradation, lipid storage/transport and insulin sensitivity. Metabolex has in-licensed the patents and the exclusive development and commercialization rights to MBX-8025 from Janssen Pharmaceutica NV, a Johnson & Johnson company.

About Metabolex

Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has three clinical-stage compounds: MBX-102/JNJ 39659100, in Phase 2/3 testing; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, now in Phase 2. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100 and MBX-2044. For additional information about Metabolex and its development pipeline, visit

SOURCE Metabolex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):